Case report of GLP-1 agonist use in an adult with cystic fibrosis-related diabetes provides safety and efficacy data for this special population.
Key findingCase report of GLP-1 agonist use in an adult with cystic fibrosis-related diabetes provides safety a
What the researchers found
Case report of GLP-1 agonist use in an adult with cystic fibrosis-related diabetes provides safety and efficacy data for this special population.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
AACE endocrinology and diabetes, 12(2), 67-70
Citation
Auth, Roger; Dougherty, Brian; Putnam, Melissa; Scully, Kevin. (2025). Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.. AACE endocrinology and diabetes, 12(2), 67-70. https://doi.org/10.1016/j.aed.2025.03.011